<DOC>
	<DOC>NCT00435695</DOC>
	<brief_summary>The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses. This study will use a medical imaging technique called Positron Emission Tomography (PET) which uses an imaging agent called [11C]-WAY100635.</brief_summary>
	<brief_title>Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Healthy male subjects, aged 1845 years Body weight &gt; 50 kg NonSmoker Normal ECG, heart rate and blood pressure History of any cardiac disease History of regular alcohol consumption averaging &gt;14 drinks/week Current or recent gastrointestinal disease; History of psychiatric illness including any history of suicidal attempts Positive for Hepatitis B and C, and HIV. History of drug abuse. Exposure to research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden Family history of cancer (one or more firstdegree relative diagnosed before the age of 55). Suffers from claustrophobia History or presence of neurological or psychiatric conditions Presence of a cardiac pacemaker or other implanted electronic device or metal implants</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>PET scan</keyword>
	<keyword>healthy males</keyword>
</DOC>